Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elisabetta Melloni

Showing results (1-10 of 65) with videos related to

Pageof 7
Sort By:
Investigational New Drugs|January 13, 2012
SOCS1 is significantly up-regulated in Nutlin-3-treated p53wild-type B chronic lymphocytic leukemia (B-CLL) samples and shows an inverse correlation with miR-155Maria Grazia di Iasio, Alessia Norcio, Elisabetta Melloni, et al.
Nutrition (Burbank, Los Angeles County, Calif.)|December 15, 2012
Release of a specific set of proinflammatory adipokines by differentiating 3T3-L1 cellsElisabetta Melloni, Giorgio Zauli, Claudio Celeghini, et al.
Investigational New Drugs|November 17, 2012
Sorafenib inhibits in vitro osteoclastogenesis by down-modulating Mcl-1Erika Rimondi, Paola Secchiero, Elisabetta Melloni, et al.
Journal of Leukocyte Biology|November 14, 2007
Combined treatment of CpG-oligodeoxynucleotide with Nutlin-3 induces strong immune stimulation coupled to cytotoxicity in B-chronic lymphocytic leukemic (B-CLL) cellsPaola Secchiero, Elisabetta Melloni, Mario Tiribelli, et al.
Current Pharmaceutical Design|August 12, 2008
Potential role of PKC inhibitors in the treatment of hematological malignanciesCarlo Mischiati, Elisabetta Melloni, Federica Corallini, et al.
Cells|February 24, 2019
Targeting mTOR in Acute Lymphoblastic LeukemiaCarolina Simioni, Alberto M Martelli, Giorgio Zauli, et al.
International Journal of Molecular Sciences|May 5, 2021
MitoQ Is Able to Modulate Apoptosis and InflammationElisa Piscianz, Alessandra Tesser, Erika Rimondi, et al.
Blood|June 24, 2004
TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSFGiorgio Zauli, Erika Rimondi, Vanessa Nicolin, et al.
Journal of Experimental Pharmacology|September 10, 2025
Targeting Intestinal Permeability for Graft-versus-Host Disease Treatment: A Therapeutic Perspective with DefibrotideErika Rimondi, Elisabetta Melloni, Paola Secchiero, et al.
Biomolecules|October 23, 2021
Mevalonate Kinase Deficiency and Squalene Synthase Inhibitor (TAK-475): The Balance to Extinguish the InflammationErika Rimondi, Erica Valencic, Alberto Tommasini, et al.
Pageof 7

Showing results (1-10 of 65) with videos related to

Sort By:
Pageof 7
Investigational New Drugs|January 13, 2012
SOCS1 is significantly up-regulated in Nutlin-3-treated p53wild-type B chronic lymphocytic leukemia (B-CLL) samples and shows an inverse correlation with miR-155Maria Grazia di Iasio, Alessia Norcio, Elisabetta Melloni, et al.
Nutrition (Burbank, Los Angeles County, Calif.)|December 15, 2012
Release of a specific set of proinflammatory adipokines by differentiating 3T3-L1 cellsElisabetta Melloni, Giorgio Zauli, Claudio Celeghini, et al.
Investigational New Drugs|November 17, 2012
Sorafenib inhibits in vitro osteoclastogenesis by down-modulating Mcl-1Erika Rimondi, Paola Secchiero, Elisabetta Melloni, et al.
Journal of Leukocyte Biology|November 14, 2007
Combined treatment of CpG-oligodeoxynucleotide with Nutlin-3 induces strong immune stimulation coupled to cytotoxicity in B-chronic lymphocytic leukemic (B-CLL) cellsPaola Secchiero, Elisabetta Melloni, Mario Tiribelli, et al.
Current Pharmaceutical Design|August 12, 2008
Potential role of PKC inhibitors in the treatment of hematological malignanciesCarlo Mischiati, Elisabetta Melloni, Federica Corallini, et al.
Cells|February 24, 2019
Targeting mTOR in Acute Lymphoblastic LeukemiaCarolina Simioni, Alberto M Martelli, Giorgio Zauli, et al.
International Journal of Molecular Sciences|May 5, 2021
MitoQ Is Able to Modulate Apoptosis and InflammationElisa Piscianz, Alessandra Tesser, Erika Rimondi, et al.
Blood|June 24, 2004
TNF-related apoptosis-inducing ligand (TRAIL) blocks osteoclastic differentiation induced by RANKL plus M-CSFGiorgio Zauli, Erika Rimondi, Vanessa Nicolin, et al.
Journal of Experimental Pharmacology|September 10, 2025
Targeting Intestinal Permeability for Graft-versus-Host Disease Treatment: A Therapeutic Perspective with DefibrotideErika Rimondi, Elisabetta Melloni, Paola Secchiero, et al.
Biomolecules|October 23, 2021
Mevalonate Kinase Deficiency and Squalene Synthase Inhibitor (TAK-475): The Balance to Extinguish the InflammationErika Rimondi, Erica Valencic, Alberto Tommasini, et al.
Pageof 7